Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Updated 2019. Accessed January 12, 2021.
   Google Scholar
• Rutstein SE, Ananworanich J, Fidler S, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. J Int AIDS Soc. 2017;20(1):21579.
   PubMed Web of Science ®Google Scholar
• Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205(1):87–96.
   PubMed Web of Science ®Google Scholar
• Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9(3):e1001196.
   PubMed Web of Science ®Google Scholar
• Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7(8):e43754.
   PubMed Web of Science ®Google Scholar
• Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3):207–217.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407(6803):523–526.
   PubMed Web of Science ®Google Scholar
• Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543.
   PubMed Web of Science ®Google Scholar
• Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77(21):11708–11717.
   PubMed Web of Science ®Google Scholar
• Nozza S, Poli A, Ripa M, et al. Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. J Antimicrob Chemother. 2017;72(2):632–633.
   Web of Science ®Google Scholar
• Prevention Access Campaign. Consensus statement. https://www.preventionaccess.org/consensus. Issued 2016. Accessed January 12, 2021.
   Google Scholar
• National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. https://www.cdc.gov/hiv/pdf/risk/art/cdc-hiv-art-viral-suppression.pdf. Published 2020. Accessed January 12, 2021.
   Google Scholar
• Centers for Disease Control and Prevention, Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. http://dx.doi.org/10.15620/cdc.23447 Published 2014. Accessed February 11, 2021.
   Google Scholar
• Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191(9):1410–1418.
   PubMed Web of Science ®Google Scholar
• Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. 2020;71(12):3110–3117.
   Web of Science ®Google Scholar
• Lathouwers E, Wong EY, Luo D, Seyedkazemi S, De Meyer S, Brown K. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials. 2017;18(5–6):196–204.
   PubMed Web of Science ®Google Scholar
• Clay PG, Nag S, Graham CM, Meta NS. Analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine. 2015;94(42):e1677.
   PubMed Web of Science ®Google Scholar
• Hardy H, Luo D, Israel D, Simonson RB, Dunn K. Treatment adherence and virologic response over 48 weeks among patients rapidly initiating darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the DIAMOND study. Poster presented at: 14th International Conference on HIV Treatment and Prevention Adherence; June 17–19, 2019; Miami, FL.
   Google Scholar
• Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(5):e1002015.
   PubMed Web of Science ®Google Scholar
• Koenig SP, Dorvil N, Devieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med. 2017;14(7):e1002357.
   PubMed Web of Science ®Google Scholar
• Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial. JAMA. 2018;319(11):1103–1112.
   PubMed Web of Science ®Google Scholar
• Coffey S, Bacchetti P, Sachdev D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS. 2019;33(5):825–832.
   PubMed Web of Science ®Google Scholar
• Halperin J, Butler I, Conner K, et al. Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans. AIDS Patient Care Stds. 2018;32(2):39–41.
   Web of Science ®Google Scholar
• Colasanti J, Sumitani J, Mehta CC, et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States. Open Forum Infect Dis. 2018;5(6):ofy104.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Understanding the HIV care continuum. https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf. Published 2019. Accessed February 11, 2021.
   Google Scholar
• World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/255884/9789241550062-eng.pdf?sequence=1. Published 2017. Accessed December 22, 2020.
   Google Scholar
• Dunn K, Simonson RB, Luo D, et al. High levels of patient satisfaction and virologic suppression at 48 weeks in newly diagnosed black/African American individuals rapidly initiating darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the DIAMOND study. Poster presented at: National Medical Association Annual Convention and Scientific Assembly; July 27–31, 2019; Honolulu, HI.
   Google Scholar
• Lathouwers E, Seyedkazemi S, Luo D, Brown K, De Meyer S, Wong EY. Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naive and treatment-experienced patients with human immunodeficiency virus-1 infection. HIV Res Clin Pract. 2020;21(2–3):83–89.
   PubMed Web of Science ®Google Scholar
• Girometti N, Nwokolo N, McOwan A, Whitlock G. Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation. Antivir Ther. 2017;22(1):77–80.
   PubMed Web of Science ®Google Scholar